JonesTrading 2023 Healthcare Summit
Oct 10, 2023 • 1:45pm EDT
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
Read Press ReleaseUpcoming Events
Latest Financial Results
Q2 2023
Quarter Ended Jun 30, 2023
Email Alerts
Stay informed and receive company updates straight to your inbox.
Stock Information
Company Overview
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders.
Investor Contact Information
Company
Ocuphire Pharma, Inc.
37000 Grand River Ave., Suite 120
Farmington Hills, MI 48335
T: 248-957-9024
[email protected]
Investor Relations
LifeSci Advisors
250 West 55th Street, Suite 3401
New York, NY 10019
T: 646-889-1200
[email protected]
CoreIR
377 Oak Street, Level 2
Garden City, New York 11530
T: 212-655-0924
[email protected]
Transfer Agent
American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449
www.astfinancial.com